Quantcast

Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes Pradaxa Bleeding Claims Pending in Federal Litigation Now Exceed 1,000

June 11, 2013

The Firm is currently investigating Pradaxa lawsuits on behalf of alleged victims of life-threatening Pradaxa bleeding.

New York, New York (PRWEB) June 11, 2013

Pradaxa lawsuit claims continue to mount in the federal multidistrict litigation now underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to court filings 1,037 Pradaxa bleeding lawsuits have been filed in the proceeding, while the number of plaintiffs with claims in the litigation has grown to 1,104. All of the lawsuits allege use of the blood thinner caused plaintiffs to suffer from life-threatening episodes of Pradaxa bleeding, and accuse Boehringer Ingelheim of failing to adequately warn that there was no readily-available antidote for the serious internal bleeding that can sometimes accompany use of the drug. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation — MDL No. 2385)

“It was recently reported that sales of Pradaxa passed the $1 billion threshold that denotes blockbuster status in the pharmaceutical industry.* Considering the frequency with which it is prescribed, it´s not at all surprising that the number of Pradaxa bleeding claims pending in the federal litigation is growing so rapidly,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Pradaxa lawsuit evaluations to patients who have suffered serious internal bleeding, allegedly due to this drug.

Pradaxa Bleeding

Pradaxa, which is used to prevent strokes in atrial fibrillation patients, was approved by the U.S. Food & Drug Administration (FDA) in October 2010. The drug was marketed as an improvement over warfarin, a blood thinner that has been on the market for decades, as it is not necessary for Pradaxa patients to undergo the frequent blood tests that are required by warfarin use. Last December, however, Bloomberg.com reported that regulators in several countries have issued Pradaxa bleeding alerts since the drug was first brought to market. Most concerning is the fact that there exists no readily-available antidote for the internal bleeding that can sometimes occur in Pradaxa patients. In 2011 alone, the FDA received reports of 542 deaths and 3,781 side-effect incidents tied to Pradaxa, Bloomberg.com said.**

Since then, concerns about the potentially dangerous effects of Pradaxa bleeding have continued to grow. The Institute for Safe Medicine Practices recently reported, for example, that its analysis of hemorrhage cases reported to the FDA during the second quarter of 2012 found that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding.*** Last month, the Journal of Neurosurgery published a study that showed death from brain bleeding resulting from head trauma was more likely to occur with Pradaxa than warfarin, something the study authors blamed on the drug´s lack of an antidote.****

Alleged Pradaxa bleeding victims may be entitled to compensation for their medical bills, lost wages, pain and suffering and more. Additional information on filing a Pradaxa lawsuit is available at Bernstein Liebhard LLP´s website. To arrange for a free legal consultation, please call 800-511-5092.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past 10 consecutive years.

*Reuters, April 24, 2013; reuters.com/article/2013/04/24/boehringer-results-idUSL6N0DB1WB20130424

**Bloomberg, December 11, 2012; bloomberg.com/news/2012-12-11/boehringer-sued-by-hundreds-over-bleeding-tied-to-pradaxa.html

***ISMP, January 9, 2013; ismp.org/quarterwatch/pdfs/2012Q2.pdf

****JNS, May 1, 2013; http://thejns.org/doi/abs/10.3171/2013.2.FOCUS1323?prevSearch=pradaxa&searchHistoryKey=

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.pradaxalawsuithelp.com/

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpradaxa-lawsuit/pradaxa-bleeding/prweb10822647.htm


Source: prweb



comments powered by Disqus